MORRISTOWN, N.J., Sept. 03, 2019 (GLOBE NEWSWIRE) — Melinta Therapeutics, Inc. (Nasdaq: MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, today announced that Jennifer Sanfilippo has been named interim chief executive officer and director, effective August 28, 2019. Prior […]
Click here to view original web page at www.globenewswire.com
